Gastrointestinal Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_11_2108 - Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost
W. Yu1, X. L. Fu1, X. W. Cai1, W. Feng2, Q. Zhang1, and L. T. Gao1; 1Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, 2Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China

Purpose/Objective(s): To observe the long-term survival and late adverse events of a phase I/II trial (NCT01843049) of simultaneous integrated boost (SIB) for dose escalation in unresectable thoracic esophageal cancer, in which acute toxicities were well tolerated when dose was escalated up to 70Gy.

Materials/Methods: Patients with esophageal squamous cell carcinoma were treated with escalating radiation dose of 4 levels defined as our previous works (Yu et al. Radiother Oncol 2015). A prescription dose of 62.5-64Gy was delivered to the gross tumor volume, with (Level 3 & 4) or without (Level 1 & 2) a SIB up to 70 Gy for the pre-treatment 50% SUVmax area of the primary tumor. Patients also received 2 cycles of chemotherapy of cisplatin and fluorouracil concurrently and 2 more cycles after radiotherapy.

Results: Dose escalation has been safely achieved up to Level 4 with tolerable acute toxicities as previously reported, so a phase II trial was further performed basing on Level 4. After a median follow-up duration of 21.8 (2.5-61.4) months for all 34 patients and 40.1 (13.4-61.4) months for 17 patients still alive, median overall survival time and progression free survival time were 42.4 and 11.7 months, respectively. Grade III or greater late esophageal toxicities (perforation, fistula or hemorrhage) occurred within 1 patient of Level 1 (n=5), 1 patient of Level 2 (n=10), none of Level 3 (n=5) and 7 patients of Level 4 (n=14), respectively, with median occurrence time of 5.4 months. Five patients of Level 4 finally died of grade V late esophageal toxicities.

Conclusion: Severe late esophageal toxicities might have compromised long-term survival after dose of Level 4 was delivered despite of tolerable acute toxicities. Larger numbers of patients should be enrolled into Level 3 for further assessment of treatment tolerance.

Author Disclosure: W. Yu: None. X. Cai: None. W. Feng: None. Q. Zhang: None.

Wen Yu, MD, PhD

Fudan University Shanghai Cancer Center

Biography:
Wen Yu, MD., PhD., Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University; with research and clinical experience on radiation oncology for over 10 years, especially be skilled in radiotherapy and multidisciplinary treatment of thoracic tumors, such as lung cancer, esophageal cancer and mediastinal tumors; be good at SBRT of NSCLC, concurrent chemo-radiotherapy of lung cancer and esophageal cancer, postoperative treatment of lung cancer and esophageal cancer, etc.; be dedicated to personalize radiotherapy of thoracic tumors through data mining based on functional imaging.

Presentation(s):

Send Email for Wen Yu


Assets

SU_11_2108 - Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Late Toxicities Differed Maximum Tolerated Dose Determined by Acute Toxicities: Reanalysis of a Phase I/II Trial of Dose Escalation in Unresectable Thoracic Esophageal Cancer by Simultaneous Integrated Boost